ArticleCancer medicine2026
Incidence, Mortality, and Survival Trends of Liver Cancer in the Canton of Zurich, Switzerland, Between 1980 and 2022.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global burden of liver cancer has been increasing over recent decades, whereas the incidence in Switzerland has remained relatively stable. This study assessed long-term trends in incidence, mortality, and 1- and 5-year relative survival of primary liver cancer in the Swiss canton of Zurich from 1980 to 2022, stratified by sex and age.
methodsThis population-based retrospective analysis included all primary liver cancer cases diagnosed in the canton of Zurich and registered in the Cancer Registry of the cantons of Zurich, Zug, Schaffhausen and Schwyz between 1980 and 2022. Mortality data were obtained from the Federal Statistical Office. Cases were classified according to ICD-O-3 topography and morphology and, from 2003 onward, TNM stage. Age-standardised incidence and mortality rates were calculated using the 1976 European standard population. Temporal trends were analysed using Joinpoint regression and reported as Average Annual Percentage Changes (AAPCs) with 95% confidence intervals (CIs). Relative survival was estimated using the Ederer II method and standardised according to international standards.
resultsAmong 3866 incident cases, 71.3% were hepatocellular carcinomas and 70.7% occurred in men. Overall age-standardised incidence remained stable in both men (AAPC -0.1%, 95% CI -0.6 to 0.3%) and women (-0.2%, -0.9% to 0.4%). However, incidence increased significantly among individuals younger than 65 years, particularly in women (AAPC 2.3%, 1.3%-3.3%) and men (1.2%, 0.6%-1.9%). Mortality remained broadly stable in men and increased modestly in women. One- and five-year relative survival improved substantially, from 13.8% and 3.5% in 1980-1999 to 53.9% and 25.8% in 2016-2022, respectively. Improvements were greater in men than women.
conclusionThese findings reflect major advances in liver cancer diagnosis and treatment over the past four decades. Continued prevention, targeted screening of high-risk groups, and epidemiological monitoring remain important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.